Guideline Updates: Adult & Adolescent OI Guideline

Authors of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents have recently released updates to the following sections: HPV - This update provides new recommendations regarding the cervical cancer screening interval for HIV-positive women after 3 consecutive normal Pap tests, and the use of HPV co-testing among HIV-positive  women >30 years of age. It additionally includes recommendations regarding the use of 9-valent HPV vaccine among HIV-positive females and males ages 9-26 to prevent HPV infection. HSV - This update provides new information regarding the use of suppressive acyclovir to reduce the risk of genital ulcer disease in persons who are initiating cART with a CD4 count <250 cells/mm3. Data which do not support the use of suppressive acyclovir for prevention of HSV-2 transmission in persons not on cART, or for prevention of HIV disease progression in persons on cART are also included.  Cryptococcosis – In this update, it is recommended to withhold initiating potent antiretroviral therapy for at least two weeks and up to 10 weeks after starting antifungal therapy for cryptococcosis. While the deoxycholate formulation of amphotericin B remains recommended for treatment, liposomal amphotericin B is also an appropriate choice. For those patients newly diagnosed with HIV infection with CD4 counts <50 cells/µL, testing for cryptococcosis prior to starting antiretrov...